Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03275402
Title 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Y-mAbs Therapeutics
Indications

neuroblastoma

Therapies

Omburtamab I-131

Age Groups: adult | child
Covered Countries USA | ESP | DEU | CAN


No variant requirements are available.